About Debiopharm Group
Debiopharm Group is a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management. The group in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.
Besides drug development, Debiopharm has recently developed in-house skills in the field of companion diagnostics with a view to benefit from the key opportunities in personalized medicine.
Debiopharm Group independently funds the worldwide development of all of its products while providing expertise in all areas.
Debiopharm International S.A. searches, evaluates and in-licenses promising drug candidates for development. Towards the end of the development process, the products are licensed out to pharmaceutical companies for world-wide marketing and sales.
Debiopharm Research & Manufacturing S.A. is a pharmaceutical research, development and production facility, inspected and registered with the main regulatory authorities.
Debiopharm Investment S.A. managing the group's assets. A fully dedicated team to support the sustainable growth of Debiopharm Group. The main objectives are the preservation of capital of Debiopharm Group, and the generation of regular financial incomes for Debiopharm Group's companies.
Debiopharm Innovation Fund invests in future patient care. Debiopharm Innovation Fund S.A. is the strategic investment fund of the Debiopharm Group.